Product Information
Registration Status: ActiveCUPRIPEN 250 CAPSULE 250mg is approved to be sold in Singapore with effective from 1995-05-17. It is marketed by ZYFAS MEDICAL CO, with the registration number of SIN08173P.
This product contains D-Penicillamine 250mg in the form of CAPSULE. It is approved for ORAL use.
This product is manufactured by LABORATORIOS RUBIO SA in SPAIN.
It is a Prescription Only Medicine that can only be obtained from a doctor or a dentist, or a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Description
Penicillamine is a pharmaceutical of the chelator class. The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine). It is an α-amino acid metabolite of penicillin, although it has no antibiotic properties.
Indication
For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis.
Mechanism of Action
Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson's disease. From in vitro studies which indicate that one atom of copper combines with two molecules of penicillamine. Penicillamine also reduces excess cystine excretion in cystinuria. This is done, at least in part, by disulfide interchange between penicillamine and cystine, resulting in formation of penicillamine-cysteine disulfide, a substance that is much more soluble than cystine and is excreted readily. Penicillamine interferes with the formation of cross-links between tropocollagen molecules and cleaves them when newly formed. The mechanism of action of penicillamine in rheumatoid arthritis is unknown although it appears to suppress disease activity. Unlike cytotoxic immunosuppressants, penicillamine markedly lowers IgM rheumatoid factor but produces no significant depression in absolute levels of serum immunoglobulins. Also unlike cytotoxic immunosuppressants which act on both, penicillamine in vitro depresses T-cell activity but not B-cell activity.
Pharmacokinetics
- Absorption
- rapidly but incompletely
- Distribution
- Metabolism
- Hepatic
- Elimination
Active Ingredient/Synonyms
(−)-penicillamine | (S)-2-amino-3-mercapto-3-methylbutanoic acid | (S)-3,3-dimethylcysteine | 3-mercapto-D-valine | D-(−)-penicillamine | D-penicillamine | D-β,β-dimethylcysteine | Penicillamine |
Source of information: Drugbank (External Link). Last updated on: 3rd July 18. *Trade Name used in the content below may not be the same as the HSA-registered product.